These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 31215219)

  • 41. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
    D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
    Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluating the Safety of Sodium-Glucose Cotransporter-2 Inhibitors in a Nationwide Veterans Health Administration Observational Cohort Study.
    Patil T; Cook M; Hobson J; Kaur A; Lee A
    Am J Cardiol; 2023 Aug; 201():281-293. PubMed ID: 37393731
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients.
    Uneda K; Kawai Y; Yamada T; Kinguchi S; Azushima K; Kanaoka T; Toya Y; Wakui H; Tamura K
    Sci Rep; 2021 May; 11(1):10166. PubMed ID: 33986377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.
    Bailey CJ
    Lancet Diabetes Endocrinol; 2020 Feb; 8(2):97-99. PubMed ID: 31843565
    [No Abstract]   [Full Text] [Related]  

  • 45. A practical review of diabetes mellitus type 2 treatment in primary care.
    Call JT; Cortés P; Harris DM
    Rom J Intern Med; 2022 Mar; 60(1):14-23. PubMed ID: 34333891
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination-are we exploiting their full potential in a real life setting?
    Berkovic MC; Bilic-Curcic I; Bozek T; Mahecic DH; Majanovic SK; Canecki-Varzic S; Andric J; Marusic S; Mrzljak A
    World J Diabetes; 2020 Nov; 11(11):540-552. PubMed ID: 33269065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. THE IMPACT OF GLP-1 RECEPTOR AGONISTS ON PATIENTS WITH DIABETES ON INSULIN THERAPY.
    Gyorffy JB; Keithler AN; Wardian JL; Zarzabal LA; Rittel A; True MW
    Endocr Pract; 2019 Sep; 25(9):935-942. PubMed ID: 31170363
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.
    Bonaventura A; Carbone S; Dixon DL; Abbate A; Montecucco F
    J Intern Med; 2019 Jul; 286(1):16-31. PubMed ID: 30888088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prescription Patterns of Novel Antihyperglycemic Medications.
    Ali AS; Khan M; Ortega D; Jaffery S; Lamerato LE; Budzynska K
    J Am Board Fam Med; 2022; 35(2):255-264. PubMed ID: 35379713
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Let's Be More Sensitive-How SGLT-2 Inhibitors and GLP-1 Receptor Agonists Affect β-Cell Function in Type 2 Diabetes.
    Pratley R
    J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 33074334
    [No Abstract]   [Full Text] [Related]  

  • 52. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.
    Wang K; Chen Y; Strizek A; Boye K; Gu L; Liu Y; Qu S
    Clin Ther; 2019 Oct; 41(10):2057-2065. PubMed ID: 31514971
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials.
    Chewcharat A; Takkavatakarn K; Isaranuwatchai S; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
    Int Urol Nephrol; 2020 Sep; 52(9):1733-1745. PubMed ID: 32524495
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
    Lim S; Kim KM; Nauck MA
    Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction.
    Trombara F; Cosentino N; Bonomi A; Ludergnani M; Poggio P; Gionti L; Baviera M; Colacioppo P; Roncaglioni MC; Leoni O; Bortolan F; Agostoni P; Genovese S; Marenzi G
    Cardiovasc Diabetol; 2023 Feb; 22(1):26. PubMed ID: 36747186
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study.
    Kim HS; Yoon T; Jung CH; Park JY; Lee WJ
    Diabetes Metab J; 2022 Jul; 46(4):658-662. PubMed ID: 34743486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.
    Elian V; Popovici V; Karampelas O; Pircalabioru GG; Radulian G; Musat M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396657
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-world use of glucagon-like peptide-1 receptor agonists in youth with type 2 diabetes is associated with short-term improvements in HbA1c.
    Samuels SL; Chajecki A; Hu P; Kayser M; Weyman K; Pan B; Brown EA; Van Name M; Wolf RM
    Diabetes Obes Metab; 2024 Apr; 26(4):1305-1313. PubMed ID: 38229444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [GLP-1 Receptor Agonists: For Which Patients with Type-2 Diabetes?].
    Mächler T; Wiesli P
    Praxis (Bern 1994); 2023 Apr; 112(5-6):324-328. PubMed ID: 37042408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review.
    González-González JG; Díaz González-Colmenero A; Millán-Alanís JM; Lytvyn L; Solis RC; Mustafa RA; Palmer SC; Li S; Hao Q; Alvarez-Villalobos NA; Vandvik PO; Rodríguez-Gutiérrez R
    BMJ Open; 2021 Jul; 11(7):e049130. PubMed ID: 34244276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.